Chaito, L.; Stefanoff, P.; Baruch, J.; Farah, Z.; Albuaini, M.; Ghosn, N.
Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July–December 2021. Vaccines 2024, 12, 954.
https://doi.org/10.3390/vaccines12090954
AMA Style
Chaito L, Stefanoff P, Baruch J, Farah Z, Albuaini M, Ghosn N.
Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July–December 2021. Vaccines. 2024; 12(9):954.
https://doi.org/10.3390/vaccines12090954
Chicago/Turabian Style
Chaito, Lina, Pawel Stefanoff, Joaquin Baruch, Zeina Farah, Mona Albuaini, and Nada Ghosn.
2024. "Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July–December 2021" Vaccines 12, no. 9: 954.
https://doi.org/10.3390/vaccines12090954
APA Style
Chaito, L., Stefanoff, P., Baruch, J., Farah, Z., Albuaini, M., & Ghosn, N.
(2024). Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July–December 2021. Vaccines, 12(9), 954.
https://doi.org/10.3390/vaccines12090954